GET DAILY SIGNALSAnteris Technologies (AVR): Following a Biomimetic Approach to Heart Valve Replacement
Key Takeaways
- AVR is the ticker for Anteris Technologies Global Corp., a development-stage medical device company focused on structural heart disease.
- The company's lead product is the DurAVR® Transcatheter Heart Valve (THV) System, a "biomimetic" aortic valve designed to treat severe aortic stenosis.
- Anteris is headquartered in Australia and also has operations in Minnesota, and it completed its initial public offering (IPO) on the Nasdaq in December 2024.
- As a pre-commercialization business, Anteris generates minimal revenue and posts significant net losses while funding clinical trials and manufacturing build-out.
- The company's outlook is tied to the success of its global PARADIGM pivotal trial and eventual regulatory approvals.
Company Background
Anteris Technologies Global Corp. develops minimally invasive medical devices for heart valve disease. Investors track AVR as the company works to introduce a new type of transcatheter aortic valve intended to more closely match the shape and flow characteristics of a healthy human valve. At this stage the business remains focused on clinical and development milestones rather than current earnings.
Technology and Operations
The company originated from an Australian entity and reorganized into a Delaware corporation before listing on Nasdaq under AVR in December 2024, with CHESS Depositary Interests also trading on the Australian Securities Exchange. Headquarters are in Toowong, Queensland, with additional operations in Eagan, Minnesota. Its lead candidate, the DurAVR® Transcatheter Heart Valve System, targets aortic stenosis. The balloon-expandable valve uses a single-piece biomimetic design and the company’s ADAPT® anti-calcification tissue technology. Deployment occurs via the ComASUR® delivery system. Revenue remains minimal as the firm advances clinical work and manufacturing, resulting in ongoing net losses. In January 2026 an underwritten offering and private placement with Covidien Group, a Medtronic subsidiary, provided additional capital.
Why the Stock Draws Attention
Interest centers on the large transcatheter aortic valve replacement market and the differentiated design of the DurAVR® valve, which aims to restore more natural blood flow and potentially improve durability. The global PARADIGM pivotal trial compares the valve against existing commercial options and represents a key upcoming catalyst alongside regulatory filings for PMA in the United States and CE Mark in Europe. The ADAPT® tissue platform already has a track record in other applications. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Strategic support from Medtronic and a cash position that supports ongoing trials further inform the longer-term narrative, even as the company stays pre-profit.
Key Risks to Consider
Because Anteris is not yet operating at commercial scale, investment carries notable risk. Clinical trial results, regulatory outcomes, and manufacturing execution are not assured, and setbacks could materially affect the business. The structural heart field is competitive, with established players holding significant resources and physician relationships. Additional capital raises may be needed, potentially leading to dilution. The company’s limited history as a Nasdaq-listed entity and its negative earnings and cash flow profile are also factors investors weigh carefully.
AI Screener
In my own research I often use Tickeron’s AI Screener to apply technical, fundamental, and industry filters when evaluating development-stage names. It helps surface ideas that match specific criteria without replacing deeper fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AVR's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for AVR turned positive on October 28, 2026. Looking at past instances where AVR's MACD turned positive, the stock continued to rise in 11 of 12 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AVR's RSI Indicator exited the oversold zone, 5 of 6 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 14 of 16 cases where AVR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
Following a +6.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where AVR advanced for three days, in 92 of 104 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
AVR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AVR as a result. In 19 of 24 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
The 50-day moving average for AVR moved below the 200-day moving average on November 04, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AVR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for AVR entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating fairly steady price growth. AVR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.206) is normal, around the industry mean (4.142). P/E Ratio (-2.918) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (238.095) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AVR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement